A Year In Review
The Beacon Checkpoint 2024 Landscape Review provides an in-depth analysis of the checkpoint therapy landscape, including the latest surge in preclinical activity and the evolving clinical and regulatory trends shaping the field. With over 200 new preclinical drugs identified in 2024, the landscape is expanding rapidly, driven by novel mechanisms like next-generation checkpoint targets and bispecific antibodies.
Full Version Now Available
Download this critical review to gain an in-depth analysis of the evolving checkpoint therapy landscape. With growing competition and strategic investment shifts, stay at the forefront of information in the space with Beacon’s 2024 Landscape Review.
Report Contents
The Drug Landscape
A deep dive into the ICM’s entering the clinic, drug approvals, and discontinuations.
The Trial Landscape
Analysis of checkpoint trials including phase distribution, and status updates.
The Commercial Market
A review of the checkpoint deals in 2024, analyzing financing value and investment levels.
The Future of the Checkpoint Space
A glance into the future of the checkpoint landscape and the direction of research moving forward.
Regulatory Announcements
A breakdown of all the regulatory updates in the checkpoint space in 2024.
Previous Checkpoint Landscape Reviews
Checkpoint 2024 H1 Landscape Review
An analysis of the Checkpoint landscape in H1 of 2024
You May Also Be Interested In…
What is Beacon?
Beacon is a world leading data analysis tool for preclinical and clinical trial information. With unrivalled granularity of search function, data quality, and exhaustiveness, Beacon provides timely information and gives you confidence to progress your targeted drug therapies to patients.
Learn more about how our clinical trials and drug database solutions can be tailored to your research requirements
